Dental pulp stem cell-derived extracellular vesicles for dentin-pulp complex regeneration
Originally at sciencedirect.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Dental pulp stem-cell extracellular vesicles (DPSC-EVs) show statistically significant improvements in dentin-pulp regeneration metrics, suggesting future biologic therapies that could shift endodontic practice from traditional root-canal obturation to biologically driven pulp regeneration.
Key points
- Systematic review and meta-analysis of 15 preclinical studies (n = 612 animal teeth) demonstrates a pooled standardized mean difference of 1.84 in dentin bridge thickness and 1.37 in odontoblast-like cell differentiation versus controls.
- Publication in January 2027 Journal of Dentistry (Vol. 176) positions DPSC-EV therapy as an emerging biologic alternative that may reduce the need for pulpectomy in vital-pulp cases.
- No human RCTs reported yet; timeline for clinical adoption is likely 5–7 years pending regulatory clearance and scalable manufacturing of vesicle-based medicaments.
- Endodontists and restorative dentists should monitor FDA biologic-device guidance updates and consider participation in future translational trials.
Who should care
Read the original on Journal of Dentistry
Full reporting and any paywall content live on sciencedirect.com. We summarize and score; we do not republish.
Related
- ·Regulatory
Head Start’s Oral Health Rules Face the Chopping Block
- ·Clinical
When a Tooth Extraction Becomes a Jaw-Threatening Risk
- ·Regulatory
ADA urges government to keep Head Start dental requirements in place
- ·Research
Management of acute periodontal conditions-the EFP s2k level clinical practice guideline